Efficacy and safety of co-formulated elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in HIV-positive patients: real-world data.
Ömer Fehmi TabakEsra ZerdaliOzlem AltuntaşAlper GunduzSibel BolukcuBilgül MeteInci Y NakirHayat Kumbasar KaraosmanogluDilek S YildizMeliha Meric Kocİlyas Dokmetasnull nullPublished in: International journal of STD & AIDS (2021)
Starting with or switching to E/C/F/TAF in PLWH effectively suppresses HIV infection, is associated with an increase in CD4 cell count and is well tolerated in a real-life setting. Renal functions remained stable during the treatment. E/C/F/TAF use was associated with an increase in LDL-cholesterol and triglyceride levels along with an increase in HDL-cholesterol levels.
Keyphrases
- hiv positive
- antiretroviral therapy
- low density lipoprotein
- end stage renal disease
- men who have sex with men
- ejection fraction
- newly diagnosed
- hiv infected
- chronic kidney disease
- human immunodeficiency virus
- prognostic factors
- signaling pathway
- cell therapy
- stem cells
- machine learning
- electronic health record
- big data
- combination therapy